AstraZeneca CEO says company is ‘very encouraged’ by drug trial data

Chief executive officer Pascal Soriot also described the data from the AstraZeneca lung cancer drug trial as statistically positive.

The drugmaker’s shares fell by as much as 8% earlier this month after the company released interim data from the late-stage clinical trial called Tropion-Lung01 testing an experimental precision drug called datopotamab deruxtecan. Speaking to media today after the company released better-than-expected quarterly results, Soriot said people would understand when full results are released why the company did not use that description, but he did not comment further.

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Company director claims trial to selling 34.5 tonnes of sugar without a licenceSEREMBAN: A company director has claimed trial to a charge of dealing in a controlled item, namely 34,560kg of sugar, without a valid licence.
La source: staronline - 🏆 4. / 75 Lire la suite »